With the help of the SOPHiA DDM™ Platform,
IRST has introduced a new diagnostic kit that will support
data-driven treatment planning for advanced ovarian
cancer
BOSTON and ROLLE, Switzerland, Sept. 7,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, is helping excel the use of precision medicine to
treat advanced ovarian cancer. The company today announced that the
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
"Dino Amadori", an oncology center
in Italy, is using the SOPHiA DDM™
Platform to power a new genomic test that will be used to aid
physicians in developing personalized treatment plans for those
with advanced ovarian cancer.
IRST, which is recognized for its excellence as a scientific
hospital and treatment institute for advanced oncology in the
Emilia-Romagna Region, is one of only three "Hub Centers"
authorized by the Region to perform this new test. With use of the
SOPHiA DDM™ Platform, the test will help identify patients with a
homologous recombination deficiency (HRD), which is caused by a
cell's impaired ability to repair DNA double-stranded breaks.
Identifying HRD is extremely important for oncologists, as it can
be used as a predictive biomarker for therapy response,1
and roughly half of the women affected by advanced ovarian cancer
have HRD2.
"The newly available HRD test will help our oncologists make
data-based treatment plans that can potentially save the lives of
patients who are diagnosed with, and treated for, advanced ovarian
cancer at IRST," said Daniele
Calistri, PhD., Head of Advanced and Predictive Molecular
Diagnostics Area - IRST "Dino Amadori" IRCCS Bioscience Laboratory.
"The key to success with the test is the ability to quickly turn
data into insights, so that our physicians can make the appropriate
treatment plans; that is where the SOPHiA DDM™ Platform comes in.
With the SOPHiA GENETICS technology, our team can move fast with
the confidence that they are making strong decisions rooted in
patient data."
The new test is performed on cancerous tissue using
next-generation sequencing (NGS) and produces an extensive amount
of data. The SOPHiA DDM™ Platform is a NGS-based application, that
uses artificial intelligence (AI) and machine learning to analyze
and interpret raw NGS data. The Platform combines expertly designed
testing capabilities with analytical and interpretation
functionalities to provide a streamlined bioinformatics workflow
that accelerates assessment, interpretation and reporting.
"The increase in availability of genetic sequencing across the
European market, has made the ability to quickly analyze and
interpret the large volume of data that comes with NGS even more
critical for physicians and patients," said Kevin Puylaert,
Managing Director, EMEA, SOPHiA GENETICS. "The SOPHiA DDM™ Platform
enables customers like IRST to quickly analyze sequencing data and,
as we say at SOPHiA GENETICS, find the signal in the noise. We're
excited to continue expanding our work in Italy and helping health institutions like
IRST equip their oncologists with the data needed to make precision
medicine the gold standard of care."
The SOPHiA DDM™ Platform will not only aid oncologists in
treatment planning but will help IRST further build its in-house
expertise and expand its existing database to support the continued
use of data-driven medicine.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA DDM™ Dx Homologous Recombination
Deficiency Solution is available as a CE-IVD product
for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1
https://www.sophiagenetics.com/science-hub/targeting-homologous-recombination-deficiency-hrd-in-cancer-research/
2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322589/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-the-irccs-istituto-romagnolo-per-lo-studio-dei-tumori-irst-is-live-on-the-sophia-ddm-platform-301920326.html
SOURCE SOPHiA GENETICS